SIGN UP
LOG IN
MARKET
CVM
CVM
CEL-SCI Corp
AMEX
2.660
+0.060
+2.31%
After Hours: 2.800 +0.14 +5.26% 19:40 12/08 EST
OPEN
2.620
PREV CLOSE
2.600
HIGH
2.790
LOW
2.620
VOLUME
309.57K
TURNOVER
0
52 WEEK HIGH
3.330
52 WEEK LOW
1.040
MARKET CAP
132.95M
P/E (TTM)
-3.4292
1D
5D
1M
3M
1Y
5Y
Why U Power Shares Are Trading Lower By Around 54%? Here Are Other Stocks Moving In Monday's Mid-Day Session
U power shares dipped 54% to $0.7090 on monday. Eyepoint pharmaceuticals, inc. Shares jumped 211.3% after the company announced positive results in a wet amd trial. Hawaiian holdings shares climbed 187% after alaska air group announced plans to acquire the company.
Benzinga · 4d ago
BCAB, DUNE and CDT among mid-day movers
On the move: bcab, dune and cdt among mid-day movers. Hawaiian holdings and eyepoint pharmaceuticals are among the top gainers. U power ltd and neximmune among the losers in sa's tech sector on the day's top 10 list.
Seeking Alpha · 4d ago
12 Health Care Stocks Moving In Monday's Intraday Session
Eyepoint pharmaceuticals stock rose 172.8% to $18.03 during monday's regular session. Alterity therapeutics stock increased by 122.28%. Altimmune stock rose 34.98% and altimmune's market cap stands at $636.6 million. Biomea fusion shares increased by 30.33%.
Benzinga · 4d ago
CEL-SCI spikes as U.K. picks cancer drug, Multikine for review
Cel-sci spikes as u.k. Picks cancer drug, multikine for review, as a new standard of care for head and neck cancer. Biotech's lead immunotherapy candidate is a candidate to treat newly diagnosed squamous cell carcinoma of the head.
Seeking Alpha · 4d ago
Why Is Cancer Focused CEL-SCI Stock Trading Higher Today?
Cel-sci's multikine to be evaluated as potential new standard of care for squamous cell carcinoma of the head and neck in the u.k. Cvm shares are up 41% in pre-market trading. Nice has selected the company's li injection for evaluation.
Benzinga · 4d ago
UK'S National Institute for Health And Care Excellence Selects CEL-SCI's Multikine As Potential New Standard of Care For Head & Neck Cancer
Uk's national institute for health and care excellence has selected multikine as a potential new standard of care for squamous cell carcinoma of the head and neck in the uk. Cancer research uk says an average of 12,400 cases of head & neck cancer are diagnosed each year.
Benzinga · 4d ago
Weekly Report: what happened at CVM last week (1127-1201)?
Weekly Report · 4d ago
Weekly Report: what happened at CVM last week (1120-1124)?
Weekly Report · 11/27 11:31
About CVM
CEL-SCI Corporation is a clinical-stage biotechnology company. The Company is focused on activating the immune system to fight cancer and infectious diseases. The Company is engaged in research and developing of treatments for cancer and other diseases by using the immune system. Its lead investigational therapy Multikine (Leukocyte Interleukin, Injection) is in a pivotal phase III clinical trial. Its Multikine is an investigational immunotherapy under development for the potential treatment of certain head and neck cancers. The Company is using its Ligand Epitope Antigen Presentation System (LEAPS) technology to develop various new drug candidates, CEL-4000 and CEL-2000, as potential rheumatoid arthritis therapeutic treatments. Its product candidates using its LEAPS technology are CEL-2000, CEL-4000 and DerG-PG275(Cit). The Company’s Multikine is an immunotherapy product candidate comprised of a patented defined mixture of 14 human natural cytokines.
Webull offers CEL-SCI Corporation stock information, including AMEX: CVM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CVM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.
You can practice and explore trading CVM stock methods without spending real money on the virtual paper trading platform.